Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Stock Up 6 Percent to New 52-Week High on FDA OK

NEW YORK (GenomeWeb News) — Shares in Cepheid were up 6 percent to a new 52-week high of $12.47 in mid-afternoon trading today after the company this morning said the US Food and Drug Administration cleared one of its tests.
 
As GenomeWeb Daily News reported this morning, the company’s PCR-based Xpert MRSA test is designed to detect drug-resistant Staphylococcus aureus infections.   
  
The FDA last month cleared its meningitis diagnostic.
The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.